Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a pill tame the inflammation behind brain aneurysms?

NCT ID NCT05959759

Disease control Sponsor: Beijing Tiantan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial tests whether dimethyl fumarate, an oral anti-inflammatory medication, can reduce inflammation in the walls of unruptured brain aneurysms. About 60 adults with small, unruptured aneurysms will receive either the drug or a placebo for six months. Using advanced MRI scans, researchers will compare changes in wall inflammation between the two groups to see if the drug has a calming effect.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dimethyl fumarate, an oral anti-inflammatory drug
What this could lead to
If it works, this could point toward a medication-based way to stabilize unruptured brain aneurysms and reduce the need for invasive procedures.
What could go wrong
This is a small, early-stage trial. The drug may not reduce inflammation enough to matter, and it can cause side effects like stomach upset or flushing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

60 people

The number who actually took part.

Started

Jul 2023

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female aged ≥18 years. 2. Unruptured IA of ≥3mm identified on imaging (CT, MRI or digital subtraction angiography). 3. Aneurysm wall enhancement identified by HR-VWI before treatment. 4. Ability to understand the objective of the trial with provision of written informed consent. Exclusion Criteria: 1. MRI contraindications (metallic implant, contrast allergy, claustrophobia, etc). 2. Planned treatment of the aneurysm within 6 months. 3. Current treatment with drugs that might have an anti-inflammatory effect (aspirin, statins, immunosuppressive drugs, angiotensin converting enzyme, etc.). 4. Severely impaired liver or renal function. 5. Retreatment of recurrent aneurysm. 6. Pregnant or lactating women. 7. Malignant diseases (liver disease, kidney disease, congestive heart failure, malignant tumours, etc.). 8. Poor compliance with treatment or follow--up (patients who refuse to take medication as prescribed, patients who decline imaging follow--up or blood test, etc).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aneurysm, brain are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain aneurysm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aneurysm, brain Inflammation vascular Intracranial aneurysm

Contacts and locations

Locations

  • Beijing Neurosurgical Institute & Beijing Tiantan Hospital

    Beijing, Beijing Municipality, 100070, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.